In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Singapore Updates Guidance On Labeling, Essential Principles, Change Notification And Registration

Executive Summary

Singapore has issued new guidance in four important areas of medical device regulation. The documents don't include mandates, but are intended as references for the industry and are subject to continual revision when appropriate.

You may also be interested in...

Singapore Improves Time To Market For Lower-Risk Devices

The Singapore Health Sciences Authority says regulatory changes that will provide faster market access for class A and many class B devices kicked in on June 1. The requirements for telehealth devices and high-risk devices cosmetic devices have also been clarified.

Next ASEAN Device Committee Meeting Looms, But National Regs Top Priorities

New medtech regulations in Singapore, a new medtech law in the Philippines, and another deferral of Act 737 in Malaysia were the focus of the Asian Medtech Associations Regulatory Networking discussions this month. In a break from the usual focus, there was also an update on the EU MDR and preparations for Brexit from the UK Association of HealthTech Industries (ABHI). This series is hosted by Medtech Insight and sponsored by the Asia Regulatory and Quality Consultancy (ARQon), and the Asia Regulatory Professionals Association (ARPA).

All About Value – Brexit Aside, UK Industry Sees Good Things Ahead For Healthtech Adoption

ABHI director of value and access Luella Trickett talks about the importance of real-world evidence in product development and value-based procurement in secondary care in the UK.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts